Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07673627 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Study acronym: ADAPT Forward2
StatusRecruiting
PhasePhase 2
Sponsorargenx
Started2026-07-10
View on ClinicalTrials.gov ↗

Amendment history

2026-08-20
Study Status, Contacts/Locations v2
Study sites2→3
2026-07-23
Study Status, Study Description, Contacts/Locations, References v1
Recruitment opened
Start dateestimated 2026-06-29→confirmed 2026-07-10
Study sites0→2
2026-06-23
Original filing
Argenx
56 trials monitored
See 2 trials at risk
Myasthenia Gravis
187 trials monitored
See 7 trials at risk
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2
Trial Details
NCT Number NCT07673627
Lead Sponsor argenx
Conditions AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
Enrollment 40 participants
Start Date 2026-07-10
Primary Completion 2027-10 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-09-24